Drug ID:Drug144
Drug Name:Warfarin
CID:54678486
DrugBank ID:DB00682
Modality:Small Molecule
Groups:approved
US Approved:YES
Other Approved:YES
Identifier: NCT03035058, , NCT02862132, , NCT02712866, , NCT05702879, , NCT02743806, , NCT06850727, , NCT04919252, , NCT06691061, , NCT05481619, , NCT06880744, , NCT06095596, , NCT05205603, , NCT03802214, , NCT02039505, , NCT03138655, , NCT06626165, , NCT03824561, , NCT06095128, , NCT04779307, , NCT06609
Molecular Formula:C19H16O4
Molecular Weight:308.3 g/mol
Isomeric SMILES:CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
Synonyms:warfarin; Coumafene; Zoocoumarin; Coumafen; Warfarine; Brumolin; Coumefene; Kypfarin; Solfarin; Dethmor
Phase 0: 4
Phase 1: 124
Phase 2: 55
Phase 3: 88
Phase 4: 93
Description:Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt1148 54678486 Warfarin 213 ALB Homo sapiens (human) None
dt1149 54678486 Warfarin 79001 VKORC1 Homo sapiens (human) Inhibitor
dt1150 54678486 Warfarin 8856 NR1I2 Homo sapiens (human) 20735727 None
dt1151 54678486 Warfarin 1559 CYP2C9 Homo sapiens (human) Substrate|Inducer
dt1152 54678486 Warfarin 1544 CYP1A2 Homo sapiens (human) Substrate
dt1153 54678486 Warfarin 1557 CYP2C19 Homo sapiens (human) Substrate|Inhibitor
dt1154 54678486 Warfarin 1576 CYP3A4 Homo sapiens (human) Substrate|Inducer
dt1155 54678486 Warfarin 1558 CYP2C8 Homo sapiens (human) Substrate
dt1156 54678486 Warfarin 1562 CYP2C18 Homo sapiens (human) Substrate
dt1157 54678486 Warfarin 213 ALB Homo sapiens (human) Binder|Regulator

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT03358706 A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis PHASE1 TERMINATED Janssen Research & Development, LLC Crohn Disease|Ulcerative Colitis DRUG: Ustekinumab IV Infusion|DRUG: Ustekinumab S… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

Continuous warfarin administration versus heparin bridging therapy in post colo…

PMID: 33413599
Year: 2021
Relationship Type: Treatment Score: 6.5

BACKGROUND: Endoscopic removal of colorectal adenoma is considered an effective treatment for reducing the mortality rates associated with colorectal…

View Details
A case of sulphasalazine potentiating the hypoprothombinemic effect of warfarin…

PMID: 21366655
Year: 2011
Relationship Type: Treatment Score: 6.1

WHAT IS KNOWN AND OBJECTIVE: One case report demonstrated warfarin resistance associated with sulphasalazine therapy. Our objective is to report on a…

View Details